Precision BioSciences Reports Q1 Revenue Surge to $10.8M, Narrows Loss on Clinical Progress
DTIL has more than doubled off its 52-week low of $3.53.
Summary
Precision BioSciences reported strong first-quarter 2026 results, with revenue significantly increasing to $10.8 million from $0.03 million in Q1 2025, primarily driven by collaboration agreements. The company also narrowed its net loss to $(18.4) million and improved diluted EPS to $(0.75) from $(2.21) year-over-year. Operationally, key clinical programs advanced, including PBGENE-HBV with 16 patients dosed and PBGENE-DMD initiating Phase 1/2 after receiving FDA Fast Track designation. This positive financial and clinical update follows the company's 2025 10-K, which highlighted efforts to bolster liquidity. The substantial revenue growth and progress in critical pipeline assets are material for a clinical-stage biotech, signaling potential for future value creation. Investors will be watching for upcoming data presentations for PBGENE-HBV at EASL 2026 and continued enrollment progress for PBGENE-DMD.
At the time of this announcement, DTIL was trading at $7.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $196.9M. The 52-week trading range was $3.53 to $8.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.